EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Olokizumab Improves Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis up to 106 Weeks (Results from the Open-Label Extension of Phase III Randomized Clinical Trials)

Roy M Fleischmann, Vibeke Strand, Eugen Feist, Tatiana Lisitsyna, Jeffrey A Sparks, Evgeny Nasonov, Mikhail Samsonov, Sergey Grishin, Alina Egorova, Sofiya Kuzkina, Josef S Smolen

Rheumatology and Therapy · 2026-08 · 13 (4) · 1055-1074

DOI: 10.1007/s40744-026-00852-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Rheumatology and Therapy, online erschienen am 16.05.2026. Verfasst von Roy M Fleischmann und 10 weiteren Autor:innen. Beteiligte Einrichtung: Metroplex Clinical Research Center, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA. rfleischmann@arthdocs.com. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

Biological therapyInterleukin-6-inhibitorMethotrexateOlokizumabPatient reported outcome measuresRheumatoid arthritisTNF inhibitor

Autor:innen und Institutionen

  • Metroplex Clinical Research Center, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA. rfleischmann@arthdocs.com.
  • Division of Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA, USA.
  • Rheumatology and Clinical Immunology, HELIOS Fachklinik Vogelsang/Gommern, Gommern, Germany.
  • VA Nasonova Research Institute of Rheumatology, Moscow, Russia.
  • Mass General Brigham/Brigham and Women's Hospital, Boston, MA, USA.
  • "R-Pharm" JSC, Moscow, Russia.

Zitieren

APA

Fleischmann, R. M., Strand, V., Feist, E., Lisitsyna, T., Sparks, J. A., Nasonov, E., Samsonov, M., Grishin, S., Egorova, A., Kuzkina, S., & Smolen, J. S. (2026). Olokizumab Improves Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis up to 106 Weeks (Results from the Open-Label Extension of Phase III Randomized Clinical Trials). Rheumatology and Therapy, 13(4), 1055-1074. https://doi.org/10.1007/s40744-026-00852-3

Vancouver

Fleischmann RM, Strand V, Feist E, Lisitsyna T, Sparks JA, Nasonov E, et al. Olokizumab Improves Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis up to 106 Weeks (Results from the Open-Label Extension of Phase III Randomized Clinical Trials). Rheumatology and Therapy. 2026;13(4):1055-1074. doi:10.1007/s40744-026-00852-3

BibTeX
@article{Fleischmann2026,
  author = {Fleischmann, Roy M and Strand, Vibeke and Feist, Eugen and Lisitsyna, Tatiana and Sparks, Jeffrey A and Nasonov, Evgeny and Samsonov, Mikhail and Grishin, Sergey and Egorova, Alina and Kuzkina, Sofiya and Smolen, Josef S},
  title = {Olokizumab Improves Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis up to 106 Weeks (Results from the Open-Label Extension of Phase III Randomized Clinical Trials)},
  journal = {Rheumatology and Therapy},
  year = {2026},
  volume = {13},
  number = {4},
  pages = {1055--1074},
  doi = {10.1007/s40744-026-00852-3}
}
Kostenlos starten →